Ozempic Gastroparesis Attorney: Statute of Limitations for Ozempic in Michigan

Q: What is the statute of limitations for filing an Ozempic gastroparesis lawsuit in Michigan?

In Michigan, the statute of limitations for product liability claims is generally three years from the date of injury or from when the injury was discovered, or should have been discovered, through reasonable diligence. Because gastroparesis symptoms may develop gradually, it is crucial to consult an attorney promptly to preserve your claim.

Q: How does Ozempic cause gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism for glycemic control. In some individuals, this effect can become pathological, leading to sustained gastroparesis even after discontinuation. Clinical trials show a dose-dependent increase in gastrointestinal adverse reactions, including nausea, vomiting, and abdominal pain, which are consistent with gastroparesis symptoms.

Q: Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

From General Health Awareness to Targeted Exposure Concerns

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical conditions, treatment options, and preventive care. This legacy emphasized broad awareness of wellness principles, disease mechanisms, and the importance of informed decision-making in clinical settings. Within this framework, discussions of pharmaceutical interventions were typically confined to their intended therapeutic benefits and standard risk disclosures. As the landscape of prescription drug use evolves, a more focused concern has emerged regarding the unintended consequences of widely prescribed medications. One such area involves the growing recognition of gastrointestinal complications linked to certain diabetes and weight management drugs. Specifically, the medication Ozempic has been associated with reports of gastroparesis—a condition characterized by delayed gastric emptying—among long-term users. This shift from general health education to a targeted exposure concern requires careful attention to the legal and occupational dimensions that arise when patients experience adverse effects.

The Medical Reality: Ozempic and Gastroparesis

Ozempic, the brand name for semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes mellitus. Its pharmacological action involves slowing gastric emptying, which contributes to glycemic control but also underlies a spectrum of gastrointestinal adverse reactions. Among these, gastroparesis—a condition characterized by delayed gastric emptying in the absence of mechanical obstruction—has emerged as a significant concern. Clinical presentation of gastroparesis includes nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, breath tests, or wireless motility capsules, with symptoms correlating to delayed emptying. The mechanistic pathway linking Ozempic to gastroparesis is rooted in its GLP-1 receptor agonism, which inhibits gastric motility and antral contractions while relaxing the pyloric sphincter. This effect, while intended for glucose regulation, can become pathological, leading to sustained gastroparesis even after drug discontinuation in susceptible individuals.

Clinical Evidence of Gastrointestinal Adverse Reactions

Evidence from clinical trials underscores the frequency of gastrointestinal adverse reactions associated with Ozempic. In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In the trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in ≥5% of Ozempic-treated patients with type 2 diabetes mellitus include nausea (placebo 6.1%, Ozempic 0.5 mg 15.8%, Ozempic 1 mg 20.3%), vomiting (placebo 2.3%, Ozempic 0.5 mg 5.0%, Ozempic 1 mg 9.2%), diarrhea (placebo 1.9%, Ozempic 0.5 mg 8.5%, Ozempic 1 mg 8.8%), abdominal pain (placebo 4.6%, Ozempic 0.5 mg 7.3%, Ozempic 1 mg 5.7%), and constipation (placebo 1.5%, Ozempic 0.5 mg 5.0%, Ozempic 1 mg 3.1%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of <5% include dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (placebo 0%, 0.5 mg 2.7%, 1 mg 1.1%), flatulence (placebo 0.8%, 0.5 mg 0.4%, 1 mg 1.5%), gastroesophageal reflux disease (placebo 0%, 0.5 mg 1.9%, 1 mg 1.5%), and gastritis (placebo 0.8%, 0.5 mg 0.8%, 1 mg 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data highlight a dose-dependent increase in gastrointestinal adverse events, with nausea and vomiting being particularly prominent.

Adequacy of Warnings and Legal Implications in Michigan

The adequacy of warnings regarding Ozempic and gastroparesis is a critical risk anchor. The prescribing information for Ozempic includes gastrointestinal adverse reactions in the label, but it does not explicitly list gastroparesis as a separate warning or contraindication. Instead, it notes that gastrointestinal adverse reactions occur more frequently with Ozempic than placebo and that discontinuation due to these reactions is higher. However, the label does not provide specific guidance on monitoring for gastroparesis or on the potential for prolonged gastric emptying beyond the treatment period. This gap in warnings may leave patients and healthcare providers unaware of the risk of developing a chronic condition like gastroparesis, which can persist after drug cessation. For affected patients, this raises questions about whether the manufacturer adequately communicated the risk of severe gastrointestinal harm. For patients in Michigan who have developed gastroparesis after using Ozempic, attorney-related considerations are paramount. The statute of limitations for product liability claims in Michigan is generally three years from the date of injury or from when the injury was discovered, or should have been discovered, through reasonable diligence. This timeline is crucial because gastroparesis symptoms may develop gradually, and the connection to Ozempic may not be immediately apparent. Patients should document the timeline between exposure to Ozempic and the onset of symptoms, as well as any medical diagnoses of gastroparesis. The timeline between exposure and documented harm is a key risk anchor: clinical trial data show that gastrointestinal adverse reactions often occur during dose escalation, but gastroparesis can develop after months or years of use. In the pool of placebo- and active-controlled trials and in the 2-year cardiovascular outcomes trial, the types and frequency of common adverse reactions, excluding hypoglycemia, were similar to those listed in Table 1 (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This suggests that gastrointestinal effects can persist over long-term use, and a 40-week clinical trial with 959 patients treated with Ozempic 1 mg or 2 mg once weekly as add-on to metformin with or without sulfonylurea treatment found no new safety signals (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of new safety signals does not preclude the occurrence of gastroparesis, which may be underreported or misdiagnosed as other gastrointestinal conditions.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for filing an Ozempic gastroparesis lawsuit in Michigan?

In Michigan, the statute of limitations for product liability claims is generally three years from the date of injury or from when the injury was discovered, or should have been discovered, through reasonable diligence. Because gastroparesis symptoms may develop gradually, it is crucial to consult an attorney promptly to preserve your claim.

How does Ozempic cause gastroparesis?